In a filing, Regeneron Pharmaceuticals, Inc revealed its EVP Commercial McCourt Marion unloaded Company’s shares for reported $0.84 million on Nov 01 ’24. In the deal valued at $844.61 per share,1,000 shares were sold. As a result of this transaction, McCourt Marion now holds 12,931 shares worth roughly $9.36 million.
Then, MARION E MCCOURT bought 1,000 shares, generating $844,610 in total proceeds.
Before that, RYAN ARTHUR F sold 100 shares. Regeneron Pharmaceuticals, Inc shares valued at $104,878 were divested by the Director at a price of $1048.78 per share. As a result of the transaction, RYAN ARTHUR F now holds 17,582 shares, worth roughly $12.72 million.
Leerink Partners upgraded its Regeneron Pharmaceuticals, Inc [REGN] rating to an Outperform from a a Market perform in a research note published on February 05, 2025; the price target was increased to $834 from $762. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid January from “a Buy” to “a Neutral”. Wolfe Research started covering the stock on November 15, 2024. It rated REGN as “an Outperform”.
Price Performance Review of REGN
On Tuesday, Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] saw its stock jump 1.43% to $723.47. Over the last five days, the stock has gained 6.39%. Regeneron Pharmaceuticals, Inc shares have risen nearly 1.56% since the year began. Nevertheless, the stocks have fallen -25.02% over the past one year. While a 52-week high of $1211.20 was reached on 01/08/25, a 52-week low of $642.00 was recorded on 02/04/25. SMA at 50 days reached $702.73, while 200 days put it at $930.77.
Levels Of Support And Resistance For REGN Stock
The 24-hour chart illustrates a support level at 712.98, which if violated will result in even more drops to 702.49. On the upside, there is a resistance level at 736.48. A further resistance level may holdings at 749.49. The Relative Strength Index (RSI) on the 14-day chart is 59.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 18.42, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.68%. Stochastics %K at 73.92% indicates the stock is a holding.
The most recent change occurred on November 14, 2024 when Citigroup began covering the stock and recommended ‘”a Neutral”‘ rating along with a $895 price target.
